Periodic courses of human 1–34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis-Reference-Cited by-同舟云学术

Periodic courses of human 1–34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis

Published:1987-10 Issue:5 Volume:17 Page:421-428
ISSN:0014-2972
Container-title:European Journal of Clinical Investigation
language:en
Short-container-title:Eur J Clin Invest

Author:

REEVE J.,ARLOT MONIQUE,PRICE T. R.,EDOUARD C.,HESP R.,HULME PATRICIA,ASHBY J. P.,ZANELLI JOAN M.,GREEN J. R.,TELLEZ M.,KATZ D.,SPINKS T. J.,MEUNIER P. J.

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2362.1987.tb01137.x/fullpdf

Reference35 articles.

1. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss.

2. The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures

3. Variations in strength of vertebrae with age and their relation to osteoporosis

4. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.

5. Further observations on the treatment of involutional osteoporosis with hPTH 1–34; The effects of added estrogens

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anabolic or Catabolic?—Evolution of The 20th Century Understanding of Parathyroid Hormone's Therapeutic Actions on The Skeleton;Encyclopedia of Bone Biology;2020

2. Osteoporosis – a current view of pharmacological prevention and treatment;Drug Design, Development and Therapy;2013-05

3. PTH: A future role in the management of osteoporosis?;Journal of Bone and Mineral Research;2009-12-03

4. Pharmacological Mechanisms of Therapeutics;Principles of Bone Biology;2008

5. The Anabolic Effects of Parathyroid Hormone;Osteoporosis International;2002-04